ZA200108870B - Pegylated interferon alfa-CCR5 antagonist combination HIV therapy. - Google Patents

Pegylated interferon alfa-CCR5 antagonist combination HIV therapy.

Info

Publication number
ZA200108870B
ZA200108870B ZA200108870A ZA200108870A ZA200108870B ZA 200108870 B ZA200108870 B ZA 200108870B ZA 200108870 A ZA200108870 A ZA 200108870A ZA 200108870 A ZA200108870 A ZA 200108870A ZA 200108870 B ZA200108870 B ZA 200108870B
Authority
ZA
South Africa
Prior art keywords
interferon alfa
pegylated interferon
ccr5 antagonist
antagonist combination
hiv therapy
Prior art date
Application number
ZA200108870A
Other languages
English (en)
Inventor
Mark A Laughlin
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of ZA200108870B publication Critical patent/ZA200108870B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA200108870A 1999-05-04 2001-10-26 Pegylated interferon alfa-CCR5 antagonist combination HIV therapy. ZA200108870B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30489799A 1999-05-04 1999-05-04

Publications (1)

Publication Number Publication Date
ZA200108870B true ZA200108870B (en) 2003-03-26

Family

ID=23178462

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200108870A ZA200108870B (en) 1999-05-04 2001-10-26 Pegylated interferon alfa-CCR5 antagonist combination HIV therapy.

Country Status (21)

Country Link
EP (1) EP1175224B1 (enExample)
JP (1) JP2002543144A (enExample)
CN (1) CN1349408A (enExample)
AR (1) AR023824A1 (enExample)
AT (1) ATE289516T1 (enExample)
AU (1) AU776541B2 (enExample)
BR (1) BR0010593A (enExample)
CA (1) CA2365900A1 (enExample)
DE (1) DE60018273T2 (enExample)
ES (1) ES2238277T3 (enExample)
HK (1) HK1039278B (enExample)
HU (1) HUP0202734A3 (enExample)
MX (1) MXPA01011116A (enExample)
MY (1) MY127670A (enExample)
NO (1) NO328679B1 (enExample)
NZ (1) NZ514519A (enExample)
PE (1) PE20010283A1 (enExample)
PT (1) PT1175224E (enExample)
TW (1) TWI289454B (enExample)
WO (1) WO2000066141A2 (enExample)
ZA (1) ZA200108870B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050065319A1 (en) * 2000-12-19 2005-03-24 Baroudy Bahige M. Combination method for treating viral infections
CA2517888C (en) 2003-03-14 2012-05-01 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
EP2364982A1 (en) 2003-04-18 2011-09-14 ONO Pharmaceutical Co., Ltd. Spiro-piperidine compounds as chemokine receptor antagonists and medicinal use thereof
EP1616862A4 (en) * 2003-04-18 2008-07-16 Ono Pharmaceutical Co HETEROCYCLIC NITROGEN COMPOUND AND USE THEREOF
ES2294589T3 (es) 2004-04-29 2008-04-01 F. Hoffmann-La Roche Ag Variacion de la secuencia nucleosida de ns5a como marcador.
PE20060598A1 (es) 2004-09-13 2006-08-21 Ono Pharmaceutical Co Derivado heterociclo conteniendo nitrogeno como antagonista de quimiocina ccr5
AU2006216731A1 (en) * 2005-02-23 2006-08-31 Schering Corporation Piperidinyl piperazine derivatives useful as inhibitors of chemokine receptors
US20110052612A1 (en) 2005-05-31 2011-03-03 Ono Pharmaceutical Co., Ltd. Spiropiperidine compound and medicinal use thereof
EP2657235A1 (en) 2005-10-28 2013-10-30 Ono Pharmaceutical Co., Ltd. Compound containing basic group and use thereof
US8168783B2 (en) 2005-11-18 2012-05-01 Ono Pharmaceutical Co., Ltd. Chemokine receptor antagonists and use thereof
KR20090008217A (ko) 2006-03-10 2009-01-21 오노 야꾸힝 고교 가부시키가이샤 질소 함유 복소환 유도체 및 이들을 유효 성분으로 하는 약제
WO2007132846A1 (ja) 2006-05-16 2007-11-22 Ono Pharmaceutical Co., Ltd. 保護されていてもよい酸性基を含有する化合物およびその用途
US20090325992A1 (en) 2006-07-31 2009-12-31 Ono Pharmaceutical Co., Ltd. Compound having cyclic group bound thereto through spiro binding and use thereof
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
WO2013024022A1 (en) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
AU2012338581B2 (en) 2011-11-18 2016-12-08 Nxera Pharma Uk Limited Muscarinic M1 receptor agonists
SG11201605440TA (en) 2014-01-08 2016-08-30 Immunovative Therapies Ltd Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
ES2214551T3 (es) * 1995-11-02 2004-09-16 Schering Corporation Terapia de infusion continua de citocinas a baja dosis.
GB9609932D0 (en) * 1996-05-13 1996-07-17 Hoffmann La Roche Use of IL-12 and IFN alpha for the treatment of infectious diseases
WO1998025617A1 (en) * 1996-12-13 1998-06-18 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
AR013669A1 (es) * 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos

Also Published As

Publication number Publication date
EP1175224B1 (en) 2005-02-23
JP2002543144A (ja) 2002-12-17
BR0010593A (pt) 2002-02-13
PT1175224E (pt) 2005-07-29
ES2238277T3 (es) 2005-09-01
AU776541B2 (en) 2004-09-16
HUP0202734A2 (hu) 2002-12-28
AR023824A1 (es) 2002-09-04
WO2000066141A3 (en) 2001-02-08
CA2365900A1 (en) 2000-11-09
TWI289454B (en) 2007-11-11
DE60018273D1 (de) 2005-03-31
DE60018273T2 (de) 2005-08-18
NO20015367L (no) 2002-01-03
NO328679B1 (no) 2010-04-26
NZ514519A (en) 2003-07-25
MXPA01011116A (es) 2002-06-04
HK1039278B (en) 2005-06-30
CN1349408A (zh) 2002-05-15
WO2000066141A2 (en) 2000-11-09
HK1039278A1 (en) 2002-04-19
MY127670A (en) 2006-12-29
PE20010283A1 (es) 2001-03-16
AU4681500A (en) 2000-11-17
HUP0202734A3 (en) 2003-11-28
EP1175224A2 (en) 2002-01-30
ATE289516T1 (de) 2005-03-15
NO20015367D0 (no) 2001-11-02

Similar Documents

Publication Publication Date Title
ZA200108870B (en) Pegylated interferon alfa-CCR5 antagonist combination HIV therapy.
MXPA02002898A (es) Pirazolopirimidinas como agentes terapeuticos.
MXPA03003456A (es) Terapia de combinacion de ribavirina e interferon alfa pegilado contra el hcv.
EP1187827A4 (en) ANTIVIRAL ACTIVE SUBSTANCE
HUP0105142A3 (en) 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
GB9912350D0 (en) Modified cytokine
MXPA03001419A (es) Combinacion terapeutica de un inhibidor de la proteina de transferencia de esteres de colesterol y atorvastatina.
PL355109A1 (en) Tert.
IL148163A0 (en) Iv guard
ZA200204325B (en) Area Denial.
ZA200203707B (en) Pharmaceutical combinations.
GB9930079D0 (en) Medicaments
GB9930071D0 (en) Medicaments
GB9911802D0 (en) Therapeutic combination
GB9911803D0 (en) Therapeutic combination
ZA200201502B (en) Safety syringe.
AU2002222557A1 (en) Interferon therapeutic effect-potentiating agents
ZA200110454B (en) Pharmaceutical complex.
ZA200110046B (en) Therapeutic agents.
AU3714800A (en) Hiv therapy
GB0029720D0 (en) I.S machine7544232001
SI1175224T1 (en) Pegylated interferon alfa-ccr5 antagonist combination hiv therapy
GB9930083D0 (en) Medicaments
GB9924990D0 (en) Medicaments
MXPA01010701A (es) Vacuna.